|
| Public Act 103-0245
|
| SB1987 Enrolled | LRB103 25792 RLC 57149 b |
|
|
AN ACT concerning criminal law.
|
Be it enacted by the People of the State of Illinois,
|
represented in the General Assembly:
|
Section 5. The Illinois Controlled Substances Act is |
amended by changing Section 204 as follows:
|
(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) |
Sec. 204. (a) The controlled substances listed in this |
Section are
included in Schedule I. |
(b) Unless specifically excepted or unless listed in |
another
schedule, any of the following opiates, including |
their isomers,
esters, ethers, salts, and salts of isomers, |
esters, and ethers,
whenever the existence of such isomers, |
esters, ethers and salts is
possible within the specific |
chemical designation: |
(1) Acetylmethadol; |
(1.1) Acetyl-alpha-methylfentanyl |
(N-[1-(1-methyl-2-phenethyl)-
|
4-piperidinyl]-N-phenylacetamide); |
(2) Allylprodine; |
(3) Alphacetylmethadol, except
|
levo-alphacetylmethadol (also known as levo-alpha-
|
acetylmethadol, levomethadyl acetate, or LAAM); |
(4) Alphameprodine; |
|
(5) Alphamethadol; |
(6) Alpha-methylfentanyl
|
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
|
propanilido) piperidine; |
(6.1) Alpha-methylthiofentanyl
|
(N-[1-methyl-2-(2-thienyl)ethyl-
|
4-piperidinyl]-N-phenylpropanamide); |
(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); |
(7.1) PEPAP
|
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); |
(8) Benzethidine; |
(9) Betacetylmethadol; |
(9.1) Beta-hydroxyfentanyl
|
(N-[1-(2-hydroxy-2-phenethyl)-
|
4-piperidinyl]-N-phenylpropanamide); |
(10) Betameprodine; |
(11) Betamethadol; |
(12) Betaprodine; |
(13) Clonitazene; |
(14) Dextromoramide; |
(15) Diampromide; |
(16) Diethylthiambutene; |
(17) Difenoxin; |
(18) Dimenoxadol; |
(19) Dimepheptanol; |
|
(20) Dimethylthiambutene; |
(21) Dioxaphetylbutyrate; |
(22) Dipipanone; |
(23) Ethylmethylthiambutene; |
(24) Etonitazene; |
(25) Etoxeridine; |
(26) Furethidine; |
(27) Hydroxpethidine; |
(28) Ketobemidone; |
(29) Levomoramide; |
(30) Levophenacylmorphan; |
(31) 3-Methylfentanyl
|
(N-[3-methyl-1-(2-phenylethyl)-
|
4-piperidyl]-N-phenylpropanamide); |
(31.1) 3-Methylthiofentanyl
|
(N-[(3-methyl-1-(2-thienyl)ethyl-
|
4-piperidinyl]-N-phenylpropanamide); |
(32) Morpheridine; |
(33) Noracymethadol; |
(34) Norlevorphanol; |
(35) Normethadone; |
(36) Norpipanone; |
(36.1) Para-fluorofentanyl
|
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
4-piperidinyl]propanamide); |
(37) Phenadoxone; |
|
(38) Phenampromide; |
(39) Phenomorphan; |
(40) Phenoperidine; |
(41) Piritramide; |
(42) Proheptazine; |
(43) Properidine; |
(44) Propiram; |
(45) Racemoramide; |
(45.1) Thiofentanyl
|
(N-phenyl-N-[1-(2-thienyl)ethyl-
|
4-piperidinyl]-propanamide); |
(46) Tilidine; |
(47) Trimeperidine; |
(48) Beta-hydroxy-3-methylfentanyl (other name:
|
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
|
N-phenylpropanamide); |
(49) Furanyl fentanyl (FU-F); |
(50) Butyryl fentanyl; |
(51) Valeryl fentanyl; |
(52) Acetyl fentanyl; |
(53) Beta-hydroxy-thiofentanyl; |
(54) 3,4-dichloro-N-[2-
|
(dimethylamino)cyclohexyl]-N-
|
methylbenzamide (U-47700); |
(55) 4-chloro-N-[1-[2-
|
(4-nitrophenyl)ethyl]-2-piperidinylidene]-
|
|
benzenesulfonamide (W-18); |
(56) 4-chloro-N-[1-(2-phenylethyl)
|
-2-piperidinylidene]-benzenesulfonamide (W-15); |
(57) acrylfentanyl (acryloylfentanyl). |
(c) Unless specifically excepted or unless listed in |
another
schedule, any of the following opium derivatives, its |
salts, isomers
and salts of isomers, whenever the existence of |
such salts, isomers and
salts of isomers is possible within |
the specific chemical designation: |
(1) Acetorphine; |
(2) Acetyldihydrocodeine; |
(3) Benzylmorphine; |
(4) Codeine methylbromide; |
(5) Codeine-N-Oxide; |
(6) Cyprenorphine; |
(7) Desomorphine; |
(8) Diacetyldihydromorphine (Dihydroheroin); |
(9) Dihydromorphine; |
(10) Drotebanol; |
(11) Etorphine (except hydrochloride salt); |
(12) Heroin; |
(13) Hydromorphinol; |
(14) Methyldesorphine; |
(15) Methyldihydromorphine; |
(16) Morphine methylbromide; |
(17) Morphine methylsulfonate; |
|
(18) Morphine-N-Oxide; |
(19) Myrophine; |
(20) Nicocodeine; |
(21) Nicomorphine; |
(22) Normorphine; |
(23) Pholcodine; |
(24) Thebacon. |
(d) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
hallucinogenic substances, or which
contains any of its salts, |
isomers and salts of isomers, whenever the
existence of such |
salts, isomers, and salts of isomers is possible
within the |
specific chemical designation (for the purposes of this
|
paragraph only, the term "isomer" includes the optical, |
position and
geometric isomers): |
(1) 3,4-methylenedioxyamphetamine
|
(alpha-methyl,3,4-methylenedioxyphenethylamine,
|
methylenedioxyamphetamine, MDA); |
(1.1) Alpha-ethyltryptamine
|
(some trade or other names: etryptamine;
|
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
3-(2-aminobutyl)indole; a-ET; and AET); |
(2) 3,4-methylenedioxymethamphetamine (MDMA); |
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
(also known as: N-ethyl-alpha-methyl-
|
|
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
and MDEA); |
(2.2) N-Benzylpiperazine (BZP); |
(2.2-1) Trifluoromethylphenylpiperazine (TFMPP); |
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); |
(4) 3,4,5-trimethoxyamphetamine (TMA); |
(5) (Blank); |
(6) Diethyltryptamine (DET); |
(7) Dimethyltryptamine (DMT); |
(7.1) 5-Methoxy-diallyltryptamine; |
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); |
(9) Ibogaine (some trade and other names:
|
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
indole; Tabernanthe iboga); |
(10) Lysergic acid diethylamide; |
(10.1) Salvinorin A; |
(10.5) Salvia divinorum (meaning all parts of the |
plant presently classified
botanically as Salvia |
divinorum, whether growing or not, the
seeds thereof, any |
extract from any part of that plant, and every compound,
|
manufacture, salts, isomers, and salts of
isomers whenever |
the existence of such salts, isomers, and salts of
isomers |
is possible within the specific chemical designation, |
derivative, mixture, or preparation of that plant, its
|
seeds or extracts);
|
|
(11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
(12) Peyote (meaning all parts of the plant presently |
classified
botanically as Lophophora williamsii
Lemaire, |
whether growing or not, the
seeds thereof, any extract |
from any part of that plant, and every compound,
|
manufacture, salts, derivative, mixture, or preparation of |
that plant, its
seeds or extracts); |
(13) N-ethyl-3-piperidyl benzilate (JB 318); |
(14) N-methyl-3-piperidyl benzilate; |
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
(also known as N-hydroxy-alpha-methyl-
|
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
(15) Parahexyl; some trade or other names:
|
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
dibenzo (b,d) pyran; Synhexyl; |
(16) Psilocybin; |
(17) Psilocyn; |
(18) Alpha-methyltryptamine (AMT); |
(19) 2,5-dimethoxyamphetamine
|
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); |
(20) 4-bromo-2,5-dimethoxyamphetamine
|
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
4-bromo-2,5-DMA); |
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
Some trade or other names: 2-(4-bromo-
|
2,5-dimethoxyphenyl)-1-aminoethane;
|
|
alpha-desmethyl DOB, 2CB, Nexus; |
(21) 4-methoxyamphetamine
|
(4-methoxy-alpha-methylphenethylamine;
|
paramethoxyamphetamine; PMA); |
(22) (Blank); |
(23) Ethylamine analog of phencyclidine.
|
Some trade or other names:
|
N-ethyl-1-phenylcyclohexylamine,
|
(1-phenylcyclohexyl) ethylamine,
|
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
(24) Pyrrolidine analog of phencyclidine. Some trade |
or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
PHP; |
(25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
(26) 2,5-dimethoxy-4-ethylamphetamine
|
(another name: DOET); |
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
(another name: TCPy); |
(28) (Blank); |
(29) Thiophene analog of phencyclidine (some trade
|
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
2-thienyl analog of phencyclidine; TPCP; TCP); |
(29.1) Benzothiophene analog of phencyclidine. Some |
trade or other names: BTCP or benocyclidine; |
(29.2) 3-Methoxyphencyclidine (3-MeO-PCP); |
(30) Bufotenine (some trade or other names:
|
|
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
3-(2-dimethylaminoethyl)-5-indolol;
|
5-hydroxy-N,N-dimethyltryptamine;
|
N,N-dimethylserotonin; mappine); |
(31) (Blank); |
(32) (Blank); |
(33) (Blank); |
(34) (Blank); |
(34.5) (Blank); |
(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- |
(2-methyloctan-2-yl)-6a,7, |
10,10a-tetrahydrobenzo[c]chromen-1-ol |
Some trade or other names: HU-210; |
(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- |
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
tetrahydrobenzo[c]chromen-1-ol, its isomers, |
salts, and salts of isomers; Some trade or other |
names: HU-210, Dexanabinol; |
(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- |
6,6-dimethyl-3-(2-methyloctan-2-yl)- |
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
Some trade or other names: HU-211; |
(37) (Blank); |
(38) (Blank); |
(39) (Blank); |
(40) (Blank); |
|
(41) (Blank); |
(42) Any compound structurally derived from |
3-(1-naphthoyl)indole or |
1H-indol-3-yl-(1-naphthyl)methane by substitution at the |
nitrogen atom of the indole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl whether or not further substituted |
in the indole ring to any extent, whether or not |
substituted in the naphthyl ring to any extent. Examples |
of this structural class include, but are not limited to, |
JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; |
(43) Any compound structurally derived from |
3-(1-naphthoyl)pyrrole by substitution at the nitrogen |
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
in the pyrrole ring to any extent, whether or not |
substituted in the naphthyl ring to any extent. Examples |
of this structural class include, but are not limited to, |
JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
(44) Any compound structurally derived from |
1-(1-naphthylmethyl)indene by substitution at the |
3-position of the indene ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
|
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl whether or not further substituted |
in the indene ring to any extent, whether or not |
substituted in the naphthyl ring to any extent. Examples |
of this structural class include, but are not limited to, |
JWH-176; |
(45) Any compound structurally derived from |
3-phenylacetylindole by substitution at the nitrogen atom |
of the indole ring with alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
in the indole ring to any extent, whether or not |
substituted in the phenyl ring to any extent. Examples of |
this structural class include, but are not limited to, |
JWH-167, JWH-250, JWH-251, and RCS-8; |
(46) Any compound structurally derived from |
2-(3-hydroxycyclohexyl)phenol by substitution at the |
5-position of the phenolic ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not substituted in the |
cyclohexyl ring to any extent. Examples of this structural |
class include, but are not limited to, CP 47, 497 and its |
C8 homologue (cannabicyclohexanol); |
(46.1) Any compound structurally derived from |
|
3-(benzoyl) indole with substitution at the nitrogen atom |
of the indole ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl group whether or not further |
substituted in the indole ring to any extent and whether |
or not substituted in the phenyl ring to any extent. |
Examples of this structural class include, but are not |
limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN |
48,098), and RCS-4; |
(47) (Blank); |
(48) (Blank); |
(49) (Blank); |
(50) (Blank); |
(51) (Blank); |
(52) (Blank); |
(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. |
Some trade or other names: 2C-T-7; |
(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some |
trade or other names: 2C-E; |
(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some |
trade or other names: 2C-D; |
(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some |
trade or other names: 2C-C; |
(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade |
or other names: 2C-I; |
|
(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some |
trade or other names: 2C-T-2; |
(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. |
Some trade or other names: 2C-T-4; |
(53.7) 2,5-dimethoxyphenethylamine. Some trade or |
other names: 2C-H; |
(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some |
trade or other names: 2C-N; |
(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some |
trade or other names: 2C-P; |
(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. |
Some trade or other names: 2C-G; |
(53.11) The N-(2-methoxybenzyl) derivative of any 2C |
phenethylamine referred to in subparagraphs (20.1), (53), |
(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), |
(53.8), (53.9), and (53.10) including, but not limited to, |
25I-NBOMe and 25C-NBOMe; |
(54) 5-Methoxy-N,N-diisopropyltryptamine; |
(55) (Blank); |
(56) (Blank); |
(57) (Blank); |
(58) (Blank); |
(59) 3-cyclopropoylindole with substitution at the |
nitrogen atom of the indole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
|
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indole ring to any extent, whether or not |
substituted on the cyclopropyl ring to any extent: |
including, but not limited to, XLR11, UR144, FUB-144; |
(60) 3-adamantoylindole with substitution at the |
nitrogen atom of the indole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indole ring to any extent, whether or not |
substituted on the adamantyl ring to any extent: |
including, but not limited to, AB-001; |
(61) N-(adamantyl)-indole-3-carboxamide with |
substitution at the nitrogen atom of the indole ring by |
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
cycloalkylethyl, aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indole ring to any extent, whether or not |
substituted on the adamantyl ring to any extent: |
including, but not limited to, APICA/2NE-1, STS-135; |
(62) N-(adamantyl)-indazole-3-carboxamide with |
substitution at a nitrogen atom of the indazole ring by |
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
cycloalkylethyl, aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
|
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indazole ring to any extent, whether or not |
substituted on the adamantyl ring to any extent: |
including, but not limited to, AKB48, 5F-AKB48; |
(63) 1H-indole-3-carboxylic acid 8-quinolinyl ester |
with substitution at the nitrogen atom of the indole ring |
by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
cycloalkylethyl, aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indole ring to any extent, whether or not |
substituted on the quinoline ring to any extent: |
including, but not limited to, PB22, 5F-PB22, FUB-PB-22; |
(64) 3-(1-naphthoyl)indazole with substitution at the |
nitrogen atom of the indazole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indazole ring to any extent, whether or not |
substituted on the naphthyl ring to any extent: including, |
but not limited to, THJ-018, THJ-2201; |
(65) 2-(1-naphthoyl)benzimidazole with substitution |
at the nitrogen atom of the benzimidazole ring by alkyl, |
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
|
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the benzimidazole ring to any extent, whether or not |
substituted on the naphthyl ring to any extent: including, |
but not limited to, FUBIMINA; |
(66) |
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- |
3-carboxamide with substitution on the nitrogen atom of |
the indazole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indazole ring to any extent: including, but not |
limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; |
(67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- |
indazole-3-carboxamide with substitution on the nitrogen |
atom of the indazole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indazole ring to any extent: including, but not |
limited to, ADB-PINACA, ADB-FUBINACA; |
(68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- |
indole-3-carboxamide with substitution on the nitrogen |
atom of the indole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
|
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indole ring to any extent: including, but not |
limited to, ADBICA, 5F-ADBICA; |
(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- |
3-carboxamide with substitution on the nitrogen atom of |
the indole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indole ring to any extent: including, but not |
limited to, ABICA, 5F-ABICA; |
(70) Methyl 2-(1H-indazole-3-carboxamido)-3- |
methylbutanoate with substitution on the nitrogen atom of |
the indazole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted |
on the indazole ring to any extent: including, but not |
limited to, AMB, 5F-AMB; |
(71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- |
dimethylbutanoate with substitution on the nitrogen
atom |
of the indazole ring by alkyl, haloalkyl, alkenyl,
|
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted
|
on the indazole ring to any extent: including, but not
|
|
limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; |
(72) Methyl 2-(1H-indole-3-carboxamido)-3- |
methylbutanoate with substitution on the nitrogen atom
of |
the indole ring by alkyl, haloalkyl, alkenyl,
|
cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl,
or |
2-(4-morpholinyl)ethyl, whether or not further
substituted |
on the indazole ring to any extent:
including, but not |
limited to, MMB018, MMB2201,
and AMB-CHMICA; |
(73) Methyl 2-(1H-indole-3-carboxamido)-3,3- |
dimethylbutanoate with substitution
on the nitrogen atom |
of the indole ring by alkyl,
haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl,
whether or not further substituted |
on the
indazole ring to any extent: including, but
not |
limited to, MDMB-CHMICA; |
(74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- |
indazole-3-carboxamide with
substitution on the nitrogen |
atom of the indazole
ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl |
halide,
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further
substituted |
on the indazole ring to any
extent: including, but not |
limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; |
(75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- |
|
3-carboxamide with substitution on
the nitrogen atom of |
the indole ring by alkyl,
haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl |
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl,
whether or not further substituted |
on the indazole
ring to any extent: including, but not |
limited to,
APP-PICA and 5-fluoro-APP-PICA; |
(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name |
4-AcO-DMT; |
(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade |
name 5-MeO-MIPT; |
(78) 4-hydroxy Diethyltryptamine (4-HO-DET); |
(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); |
(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); |
(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
|
(4-HO-MiPT); |
(82) Fluorophenylpiperazine; |
(83) Methoxetamine; |
(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- |
ethcathinone). |
(e) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a depressant effect on
the central nervous |
system, including its salts, isomers, and salts of
isomers |
whenever the existence of such salts, isomers, and salts of
|
|
isomers is possible within the specific chemical designation: |
(1) mecloqualone; |
(2) methaqualone; and |
(3) gamma hydroxybutyric acid. |
(f) Unless specifically excepted or unless listed in |
another schedule,
any material, compound, mixture, or |
preparation which contains any quantity
of the following |
substances having a stimulant effect on the central nervous
|
system, including its salts, isomers, and salts of isomers: |
(1) Fenethylline; |
(2) N-ethylamphetamine; |
(3) Aminorex (some other names:
|
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
salts, optical isomers, and salts of optical isomers; |
(4) Methcathinone (some other names:
|
2-methylamino-1-phenylpropan-1-one;
|
Ephedrone; 2-(methylamino)-propiophenone;
|
alpha-(methylamino)propiophenone; N-methylcathinone;
|
methycathinone; Monomethylpropion; UR 1431) and its
|
salts, optical isomers, and salts of optical isomers; |
(5) Cathinone (some trade or other names:
|
2-aminopropiophenone; alpha-aminopropiophenone;
|
2-amino-1-phenyl-propanone; norephedrone); |
(6) N,N-dimethylamphetamine (also known as:
|
N,N-alpha-trimethyl-benzeneethanamine;
|
|
N,N-alpha-trimethylphenethylamine); |
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); |
(8) 3,4-Methylenedioxypyrovalerone (MDPV); |
(9) Halogenated amphetamines and
|
methamphetamines - any compound derived from either
|
amphetamine or methamphetamine through the substitution
|
of a halogen on the phenyl ring, including, but not
|
limited to, 2-fluoroamphetamine, 3-
|
fluoroamphetamine and 4-fluoroamphetamine; |
(10) Aminopropylbenzofuran (APB):
|
including 4-(2-Aminopropyl) benzofuran, 5-
|
(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
|
benzofuran, and 7-(2-Aminopropyl) benzofuran; |
(11) Aminopropyldihydrobenzofuran (APDB):
|
including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
|
5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
|
6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
|
and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; |
(12) Methylaminopropylbenzofuran
|
(MAPB): including 4-(2-methylaminopropyl)
|
benzofuran, 5-(2-methylaminopropyl)benzofuran,
|
6-(2-methylaminopropyl)benzofuran
|
and 7-(2-methylaminopropyl)benzofuran. |
(g) Temporary listing of substances subject to emergency |
scheduling.
Any material, compound, mixture, or preparation |
|
that contains any quantity
of the following substances: |
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
(benzylfentanyl), its optical isomers, isomers, salts,
and |
salts of isomers; |
(2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- |
phenylpropanamide (thenylfentanyl),
its optical isomers, |
salts, and salts of isomers. |
(h) Synthetic cathinones. Unless specifically excepted, |
any chemical compound which is not approved by the United |
States Food and Drug Administration or, if approved, is not |
dispensed or possessed in accordance with State or federal |
law, not including bupropion, structurally derived from |
2-aminopropan-1-one by substitution at the 1-position with |
either phenyl, naphthyl, or thiophene ring systems, whether or |
not the compound is further modified in one or more of the |
following ways: |
(1) by substitution in the ring system to any extent |
with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or |
halide substituents, whether or not further substituted in |
the ring system by one or more other univalent |
substituents. Examples of this class include, but are not |
limited to, 3,4-Methylenedioxycathinone (bk-MDA); |
(2) by substitution at the 3-position with an acyclic |
alkyl substituent. Examples of this class include, but are |
not limited to, 2-methylamino-1-phenylbutan-1-one |
(buphedrone); or |
|
(3) by substitution at the 2-amino nitrogen atom with |
alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by |
inclusion of the 2-amino nitrogen atom in a cyclic |
structure. Examples of this class include, but are not |
limited to, Dimethylcathinone, Ethcathinone, and |
a-Pyrrolidinopropiophenone (a-PPP); or |
Any other synthetic cathinone which is not approved by the |
United States Food and Drug Administration or, if approved, is |
not dispensed or possessed in accordance with State or federal |
law. |
(i) Synthetic cannabinoids or piperazines. Any synthetic |
cannabinoid or piperazine which is not approved by the United |
States Food and Drug Administration or, if approved, which is |
not dispensed or possessed in accordance with State and |
federal law. |
(j) Unless specifically excepted or listed in another |
schedule, any chemical compound which is not approved by the |
United States Food and Drug Administration or, if approved, is |
not dispensed or possessed in accordance with State or federal |
law, and is derived from the following structural classes and |
their salts: |
(1) Benzodiazepine class: A fused 1,4-diazepine and |
benzene ring structure with a phenyl connected to the |
1,4-diazepine ring, with any substitution(s) or |
replacement(s) on the 1,4-diazepine or benzene ring, any |
substitution(s) on the phenyl ring, or any combination |
|
thereof. Examples of this class include but are not |
limited to: Clonazolam, Flualprazolam; or |
(2) Thienodiazepine class: A fused 1,4-diazepine and |
thiophene ring structure with a phenyl connected to the |
1,4-diazepine ring, with any substitution(s) or |
replacement(s) on the 1,4-diazepine or thiophene ring, any |
substitution(s) on the phenyl ring, or any combination |
thereof. Examples of this class include but are not |
limited to: Etizolam. |
(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; |
100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. |
8-14-18.)
|
